Preventing rheumatic fever: M-protein based vaccine

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Group A beta-hemolytic Streptococcus (GAS) causes rheumatic fever (RF), but penicillin fails to prevent RF in asymptomatic infections.
• Over 40 years of vaccine development targeting GAS M-protein has yielded limited success due to strain specificity and mutation.
• GAS infections manifest in various suppurative and non-suppurative forms, with M-protein's role in many remaining unclear.

Purpose of the Study:

• To evaluate the limitations of M-protein-based vaccines for Group A Streptococcus (GAS).
• To highlight the need for alternative vaccine targets against GAS infections.
• To emphasize the potential of a broadly protective GAS vaccine.

Main Methods:

• Review of existing literature on GAS, M-protein, rheumatic fever, and vaccine development.
• Analysis of GAS strain diversity, emm gene variability, and M-protein function.
• Assessment of M-protein's role in different GAS manifestations.

Main Results:

• M-protein is strain-specific, mutates frequently, and is not uniformly present in all GAS strains.
• M-protein is not responsible for acute glomerulonephritis and its role in toxic shock syndrome is questionable.
• Evidence directly linking M-protein to rheumatic fever induction is lacking.

Conclusions:

• M-protein-based vaccines are unlikely to be effective against the diverse and evolving strains of GAS.
• A successful GAS vaccine requires identification of a stable, universally present epitope.
• Preventing GAS infection through a broadly effective vaccine could prevent RF and other associated diseases.